All
FDA Approves Darzalex Combination for Newly Diagnosed Multiple Myeloma
May 8th 2018The Food and Drug Administration (FDA) granted approval to Darzalex (daratumumab) in combination with Velcade (bortezomib), melphalan and prednisone – also known as VMP – for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant (ASCT).
Tecentriq Granted Priority Review to Treat Lung Cancer
May 7th 2018The FDA has granted a priority review to a supplemental biologics license application (sBLA) for Tecentriq (atezolizumab) to be used in combination with Avastin (bevacizumab), carboplatin and paclitaxel for the first-line treatment of patients with metastatic nonsquamous non–small cell lung cancer (NSCLC).
High Percentage of Caregivers Report Feeling Depressed, Study Finds
May 5th 2018Eighty-nine percent of caregivers of young adult colorectal cancer survivors are depressed because they can’t take the pain away, according to findings from the Raymond Foundation, an advocacy organization that aims to eradicate colon cancer.
FDA Approves Combination for Rare Thyroid Cancer Type
May 4th 2018The Food and Drug Administration (FDA) approved the two-drug combination Tafinlar (dabrafenib) and Mekinist (trametinib) to treat patients with metastatic or unresectable anaplastic thyroid cancer (ATC), whose tumors harbor the BRAF V600E mutation.
Immunotherapy in GU Cancers: Combinations Are the Next Step
May 4th 2018Immunotherapy is making landmark change in the treatment of patients with genitourinary (GU) cancers, with bladder cancer being the pioneer in the field, having five FDA-approved checkpoint inhibitors. But kidney cancer is not far behind, with a breakthrough therapy designation granted for a Keytruda (pembrolizumab) combination this past January.